News
Sarepta Therapeutics (SRPT) stock drops as the company faces potential FDA-mandated studies after safety concerns over its ...
For Sarepta, the hits keep coming, with several downgrades in the past week after it was forced to temporarily take its ...
Sarepta Therapeutics (SRPT) stock is downgraded at Bank of America based on safety concerns related to the company's Elevidys gene therapy for Duchenne. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results